partnering

News

Third strike for GSK/Merck as bintrafusp alfa flubs again

GlaxoSmithKline's big gamble on Merck KGaA's bintrafusp alfa has gone from bad to worse, after the drug failed yet another mid-stage trial.

News

BMS buys into AI-designed immune drug from Exscientia

Bristol Myers Squibb has exercised an option on an immune-modulating drug candidate developed by UK artificial intelligence specialist Exscientia, paying $20 million for the buy-in as part

News

Ipsen forges $1bn alliance with Exicure on neurodegenerative...

Ipsen's new chief executive David Loew pledged to ramp up spending on the company's pipeline when he took the helm last year, and a flurry of licensing deals in the last few weeks shows tha

News

AbbVie, Calico raise their age-related disease alliance fund...

AbbVie and Alphabet spin-out Calico Life Sciences have agreed to fund their seven-year-old partnership seeking treatments for diseases of ageing with another $500 million apiece.

News

Regeneron, AZ team up on drugs for obesity "superpower" gene

AstraZeneca has formed a partnership with Regeneron to investigate the potential of treating obesity using drugs directed at GPR75, a protective gene identified by scientists at the Regener

News

Biogen builds MS pipeline via $125m deal with China's InnoCa...

Biogen has moved to shore up its besieged multiple sclerosis franchise by licensing a BTK inhibitor from Chinese biotech InnoCare currently in mid-stage clinical testing.

Third strike for GSK/Merck as bintrafusp alfa flubs again

BMS buys into AI-designed immune drug from Exscientia

Ipsen forges $1bn alliance with Exicure on neurodegenerative...

AbbVie, Calico raise their age-related disease alliance fund...

Regeneron, AZ team up on drugs for obesity "superpower" gene

Biogen builds MS pipeline via $125m deal with China's InnoCa...

ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of o...

Discover a new era of healthcare panel engagement: Grounded ...

partnering

Editor's Picks